Immunome (NASDAQ:IMNM) Price Target Cut to $25.00 by Analysts at Guggenheim

Immunome (NASDAQ:IMNM) had its price target trimmed by Guggenheim from $35.00 to $25.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also commented on IMNM. Lifesci Capital initiated coverage on Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price for the company. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Monday, March 10th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $25.50.

Immunome Stock Down 5.5 %

Shares of IMNM stock opened at $8.18 on Thursday. Immunome has a 12 month low of $8.17 and a 12 month high of $26.70. The firm has a market cap of $652.58 million, a PE ratio of -1.01 and a beta of 1.93. The stock has a 50 day moving average of $9.76 and a 200-day moving average of $11.55.

Immunome (NASDAQ:IMNM) last issued its earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, equities analysts predict that Immunome will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of the stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the transaction, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its position in Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after acquiring an additional 302,916 shares during the period. Victory Capital Management Inc. grew its holdings in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Immunome by 13.6% during the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after purchasing an additional 144,557 shares during the last quarter. Magnus Financial Group LLC grew its holdings in shares of Immunome by 107.8% during the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock worth $569,000 after purchasing an additional 27,777 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after purchasing an additional 85,580 shares during the last quarter. 44.58% of the stock is currently owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.